Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer

Surgery (United States)

Volumn 152, Issue 2, 2012, Pages 277-285

  Valentino, Joseph D ^a,b   Elliott, Victoria A ^b   Zaytseva, Yekaterina Y ^b   Rychahou, Piotr G ^b   Mustain, W Conan ^a,b   Wang, Chi ^b   Gao, Tianyan ^a,b   Evers, B Mark ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA PROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE B; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FLUOROURACIL; HCT116 CELLS; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84864199921     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.05.006     Document Type: Article

References (25)

1. Cancer facts & figures 2011 2011 American Cancer Society Atlanta (GA)
2. A.E. van der Pool, R.A. Damhuis, J.N. Ijzermans, J.H. de Wilt, A.M. Eggermont, and R. Kranse Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series Colorectal Dis 14 2012 56 61
3. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
4. D.W. Parsons, T.L. Wang, Y. Samuels, A. Bardelli, J.M. Cummins, and L. DeLong Colorectal cancer: mutations in a signalling pathway Nature 436 2005 792
5. S. Velho, C. Oliveira, A. Ferreira, A.C. Ferreira, G. Suriano, and S. Schwartz Jr. The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 2005 1649 1654
6. P. Gulhati, Q. Cai, J. Li, J. Liu, P.G. Rychahou, and S. Qiu Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer Clin Cancer Res 15 2009 7207 7216
7. S.M. Johnson, P. Gulhati, B.A. Rampy, Y. Han, P.G. Rychahou, and H.Q. Doan Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer J Am Coll Surg 210 2010 767 768
8. P. Gulhati, K.A. Bowen, J. Liu, P.D. Stevens, P.G. Rychahou, and M. Chen mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways Cancer Res 71 2011 3246 3256
9. P.G. Rychahou, L.N. Jackson, S.R. Silva, S. Rajaraman, and B.M. Evers Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma Ann Surg 243 2006 833 842
10. P.G. Rychahou, J. Kang, P. Gulhati, H.Q. Doan, L.A. Chen, and S.Y. Xiao Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis Proc Natl Acad Sci U S A 105 2008 20315 20320
11. R.K. Thomas, A.C. Baker, R.M. Debiasi, W. Winckler, T. Laframboise, and W.M. Lin High-throughput oncogene mutation profiling in human cancer Nat Genet 39 2007 347 351
12. W. De Roock, D.J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, and S. Siena Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
13. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430
14. Q.B. She, E. Halilovic, Q. Ye, W. Zhen, S. Shirasawa, and T. Sasazuki 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors Cancer Cell 18 2010 39 51
15. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat Rev Drug Discov 8 2009 129 138
16. P.G. Rychahou, L.N. Jackson, B.J. Farrow, and B.M. Evers RNA interference: mechanisms of action and therapeutic consideration Surgery 140 2006 719 725
17. C.V. Pecot, G.A. Calin, R.L. Coleman, G. Lopez-Berestein, and A.K. Sood RNA interference in the clinic: challenges and future directions Nat Rev Cancer 11 2011 59 67
18. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, and C.A. Alabi Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
19. P.G. Rychahou, C.A. Murillo, and B.M. Evers Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL) Surgery 138 2005 391 397
20. Y. Samuels, L.A. Diaz Jr., O. Schmidt-Kittler, J.M. Cummins, L. Delong, and I. Cheong Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573
21. S. Shirasawa, M. Furuse, N. Yokoyama, and T. Sasazuki Altered growth of human colon cancer cell lines disrupted at activated Ki-ras Science 260 1993 85 88
22. K. Yu, L. Toral-Barza, C. Shi, W.G. Zhang, and A. Zask Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy Cancer Biol Ther 7 2008 307 315
23. A.C. Gingras, B. Raught, and N. Sonenberg eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation Annu Rev Biochem 68 1999 913 963
24. G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas, and B. Pons 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications Cancer Res 67 2007 7551 7555
25. K.L. Kahn, J.L. Adams, J.C. Weeks, E.A. Chrischilles, D. Schrag, and J.Z. Ayanian Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer JAMA 303 2010 1037 1045